CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Betnovate, betamethasone dipropionate ointment 0.1% and placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04114097
NCT04114097Phase 4Completed

The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover

Jacob Thyssen·interventional·Posted Oct 3, 2019·Updated Apr 28, 2021

In Brief

A Phase 4 clinical trial evaluating Betnovate, betamethasone dipropionate ointment 0.1% and placebo and Protopic, tacrolimus ointment 0.1% for Atopic Dermatitis and Atopic Eczema. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The investigators believe that the emerging epidemiological evidence connecting topical use of corticosteroids to the development of type 2 diabetes and osteoporosis point to potentially massive, yet clinically unacknowledged problems associated with topical corticosteroid treatment. Using state-of-the-art methodology, the present study will delineate the impact of topical corticosteroid use on insulin sensitivity and bone turnover markers in patients with atopic dermatitis and, thus, provide important data that may have implications for millions of people using topical corticosteroids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark
CollaboratorsLEO Pharma

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedOct 3, 2019
Enrollment StartAug 22, 2019
Primary CompletionMar 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.7 years ago

Interventions

Betnovate, betamethasone dipropionate ointment 0.1% and placebodrug

Explore the systemic effects of Betnovate

Protopic, tacrolimus ointment 0.1%drug

Compare the systemic effects of Betnovate to Protopic